

BIOASTER Microbiology Technology Institute

“A unique business model for innovation & acceleration”

Dr. Nathalie Garçon CEO & CSO Bioaster, France



Thursday, 15
September

3.30 – 4.30pm

Doherty Institute
Auditorium
792 Elizabeth St
Melbourne

At this presentation, Dr Nathalie Garçon, Chief Executive Officer and Chief Scientific Officer of BIOASTER Microbiology Technology Institute, will introduce the organisation and its business model as an interdisciplinary institute that brings together industry and public research through medium to long term public and private collaboration. This new business model was established with the view to ‘reconcile France with excellence’, according to former Prime Minister Michel Rocard.

Dr Garçon will examine the accelerated pace of the emergence and re-emergence of diseases and the need for alternative ways of collaborating that reduces costs and applies technology and expertise to allow products to enter the market quickly and efficiently.

Dr Garçon PharmD, PhD joined BIOASTER in July 2014. Following the successful completion of two PhDs, one in biological pharmacy and the other in immunotoxicology and immunopharmacology, Dr Garçon moved to the UK for one year as a postdoctoral research fellow at the Royal Free Hospital in London, undertaking research on liposomes in vaccines. She then moved into industry, having worked more than 20 years at GlaxoSmithKline, most recently as Vice-President and Head of Global Adjuvant at GSK vaccines.

Dr Garçon is the 2014 laureate of the Stanley Plotkin award for vaccines and vaccine technologies. She has authored over 60 papers and book chapters, is the editor of several books, and sits on the scientific committee of several journals. She holds more than 100 patents.